Navigation Links
Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Date:2/15/2011

DEERFIELD, Ill., Feb. 15, 2011 /PRNewswire/ -- Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that its Pharmaceutical Development Division has entered into strategic partnerships with Covance (NYSE: CVD) and Quintiles, two of the world's largest full-service contract research organizations.

Under terms of the agreements, Covance and Quintiles will work in close partnership with Takeda to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology. Takeda will have access to the clinical development capabilities and central laboratory services of Covance and Quintiles, with each partner company providing dedicated resources to support Takeda's development pipeline. Takeda intends to use a global program-level sourcing strategy to increase operational efficiency. Through these relationships, Takeda will move toward a fully virtual outsourcing model combining the expertise and capabilities of Takeda with those of Covance and Quintiles to improve productivity and facilitate Takeda's global growth.  

"Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations," said Robert Ahlbrandt, Ph.D., senior vice president, global development operations for Takeda's Pharmaceutical Development Division. "Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally."

About Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the largest pharmaceutical company in Japan. Takeda Pharmaceuticals International, Inc. is the hub for R&D excellence and the commercial activities in Americas and Europe as well as other strategic functions of Takeda group. It is committed to maximize the global market potential of new products and the company's international presence to realize Takeda's Mission to strive toward better health for patients through leading innovation in medicine. Additional information about Takeda is available through its corporate Web site, www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
2. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
3. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
4. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
5. Takeda Responds to FDA Advisory Committee Recommendation
6. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
7. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... YORK , January 20, 2017 ... Inc. (NASDAQ: SGYP ), Novo Nordisk A/S (NYSE: ... SCMP ), and Pernix Therapeutics Holdings Inc. (NASDAQ: ... fell on Thursday, January 19 th , 2017, finishing near ... Health Care Index dropped over 0.7%, while shares of health ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
(Date:1/20/2017)... ... ... Pastor and Overseer at The House of Yahweh has posted a new publication this week ... is a time like no other and society needs to understand the only way to ... not want to sound like an old bible beater because religion has a bad rap ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American ... announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... which allows it to provide its products to all clients at reasonable prices. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company ... bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, SC. ... scientist who was determined to create a line of products that would elevate her ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
Breaking Medicine News(10 mins):